CClinicalTrials.gg
CompletedNCT06575413Updated Jul 11, 2025

Investigating the Role and Electrophysiological Characteristics of the Human Claustrum Based on SEEG

An interventional study of Direct Electrical Stimulation in Refractory Epilepsy and Consciousness, Loss of, sponsored by Xuanwu Hospital, Beijing. Completed at 1 site in China. Open to participants aged 14 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-07-11.

Sponsored by Xuanwu Hospital, Beijing · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
14 Years to 65 Years
Sex
All
01

Study summary

This single-center prospective study aims to investigate the electrophysiological characteristics and functions of the human claustrum by analyzing clinical, imaging, and electrophysiological data from 14\~65-year-old patients with drug-resistant epilepsy.

Read the detailed description

Stereoelectroencephalography (SEEG) is a method for recording electrical activity from deep brain structures using implanted depth electrodes to provide a three-dimensional view of neuronal activity.

Direct Electrical Stimulation (DES) is a neurosurgical technique that involves delivering electrical impulses to specific brain regions through implanted electrodes to map critical functional areas and to study the connectivity of brain regions.

This study aims to investigate the electrophysiological characteristics and functions of the human claustrum by analyzing clinical, imaging, and electrophysiological data from patients aged 14 to 65 implanted intracranial electrodes , with a specific focus on electrodes targeting the claustrum. This research forms part of a broader initiative to explore the functions of cortical and subcortical regions based on SEEG.

02

Conditions studied

  • Refractory Epilepsy
  • Consciousness, Loss of

Keywords

  • Refractory Epilepsy
  • Consciousness
  • Claustrum
03

In context

Drug Resistant Epilepsy

261 studies on the registry are indexed under Drug Resistant Epilepsy; 99 are open to participants now.

This study's enrollment of 8 is below the median of 30 across 208 interventional studies indexed under Drug Resistant Epilepsy.

Browse Drug Resistant Epilepsy studies →

Lead sponsor

Xuanwu Hospital, Beijing is the lead sponsor of 346 studies on the registry; 217 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. The patients were diagnosed with drug-resistant epilepsy.
  2. The patients underwent stereoelectroencephalography (SEEG) implantation for pre-surgical evaluation of epilepsy, with at least one electrode target reaching the claustrum
  3. Participants/parents/legal guardian provide informed consent for inclusion

Exclusion criteria

Exclusion Criteria:

1. Subjects that experience surgical complications during the implant procedure will be excluded from the study

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Direct electrical stimulation of the Claustrum

    The investigators performed direct electrical stimulation of the claustrum in drug-resistant epilepsy patients underwent SEEG monitoring.The investigators observed the neural activities before, during, and after stimulation and the claustrum-cortical network to figure out the role of claustrum in consciousness and its underlying electrophysiological mechanism.

    Other: Direct Electrical Stimulation

Interventions

  • OtherDirect Electrical Stimulation

    The patients underwent SEEG with at least one electrode targeting the claustrum. The investigators used the claustrum as a target for both mapping and CCEP, recording changes in cortical electrical activity.

06

What researchers measure

Primary outcomes

  1. Patients Clinical responses Rating

    Researchers categorized patients' clinical responses as normal, mild, moderate, or severe based on their subjective clinical response.

    Time frame: During the trial(up to 3 hours for each subject)

  2. EEG power in spectral frequency bands

    Using SEEG-implanted electrodes, the investigators applied electrical stimulation of varying intensities to the CLA while observing and recording EEG power changes across six spectral frequency bands during the pre-stimulation, stimulation, and post-stimulation periods. EEG Frequency Bands * delta (1-4 Hz) * theta (5-8 Hz) * alpha (9-12 Hz) * beta (13-30 Hz) * low gamma (31-70 Hz) * high gamma (71-150 Hz)

    Time frame: During the trial(up to 3 hours for each subject)

  3. The root mean square (RMS) value of Claustrum-Cortical Evoked Potentials

    All cortical-evoked responses were averaged by time-locking the recordings to the onset of each electrical stimulus (zero) off-line, within a time window of -200 to +400 mses, to quantify the morphology. The N1 peak, identified as the first negative deflection distinguishable from the stimulus artifact, was the primary focus due to its clear visibility and reproducibility across different stimulations. The root mean square (RMS) value will be calculated for different cortical locations during time windows that encompass both the N1 peak(early response time time window) and the baseline. A paired one-sample t-test will be used to compare the RMS values in the early response time window across different cortical sites with the RMS values in the baseline.

    Time frame: During the trial(up to 3 hours for each subject)

07

Study locations

1 site
  • Xuanwu Hospital,Capital Medical University
    Beijing, Beijing Municipality 100053, China
08

References and documents

Publications

  • Cheng Y, Zheng Y, Wang W, Ai H, Wang X, Xu C, Wang X, Hu D, Wang Z, Lu R, Huang Z, Hou Y, Chen W, Ren L. Disruption of the claustrum-ACC pathway contributes to human mind blanking. Neurobiol Dis. 2026 Jul 4:107520. doi: 10.1016/j.nbd.2026.107520. Online ahead of print. PubMed 42401244 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06575413
Lead sponsor
Xuanwu Hospital, Beijing
Responsible party
Liankun_Ren (Professor, Xuanwu Hospital, Beijing) — Principal investigator
First posted
Aug 28, 2024
Start date
May 27, 2024
Primary completion
Dec 30, 2024
Completion
Mar 5, 2025
Last update
Jul 11, 2025

Study contacts

Liankun Ren
principal investigator · Xuanwu Hospital, Beijing

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion